The clinical consequences of functional adrenal uptake in the absence of cross-sectional mass on FDG-PET/CT in oncology patients

BackgroundA large proportion of the huge global burden of extrapulmonary tuberculosis (EPTB) cases are treated empirically without accurate definition of disease sites and extent of multi-organ disease involvement. Positron emission tomography (PET) imaging using 2-deoxy-2-(fluorine-18) fluoro-d-glucose (18F-FDG) in tuberculosis could be a useful imaging technique for localising disease sites and extent of disease.MethodsWe conducted a study of HIV-negative adult patients with a new clinical diagnosis of EPTB across eight centres located in six countries: India, Pakistan, Thailand, South Africa, Serbia and Bangladesh, to assess the extent of disease and common sites involved at first presentation. 18F-FDG PET/computed tomography (CT) scans were performed within 2 weeks of presentation.Findings358 patients with EPTB (189 females; 169 males) were recruited over 45 months, with an age range of 18–83 years (females median 30 years; males median 38 years). 350 (98%) out of 358 patients (183 female, 167 male) had positive scans. 118 (33.7%) out of 350 had a single extrapulmonary site and 232 (66.3%) out of 350 had more than one site (organ) affected. Lymph nodes, skeleton, pleura and brain were common sites. 100 (28%) out of 358 EPTB patients had 18F-FDG PET/CT-positive sites in the lung. 110 patients were 18F-FDG PET/CT-positive in more body sites than were noted clinically at first presentation and 160 patients had the same number of positive body sites.Interpretation18F-FDG PET/CT scan has potential for further elucidating the spectrum of disease, pathogenesis of EPTB and monitoring the effects of treatment on active lesions over time, and requires longitudinal cohort studies, twinned with biopsy and molecular studies.

Download Full-text

Comparison between anatomical cross-sectional imaging and 18F-FDG PET/CT in the staging, restaging, treatment response, and long-term surveillance of squamous cell head and neck cancer

Nuclear Medicine Communications ◽

10.1097/mnm.0000000000000022 ◽

2014 ◽

Vol 35 (2) ◽

pp. 123-134 ◽

Cited By ~ 32

Author(s):

Laura Evangelista ◽

Anna Rita Cervino ◽

Sotirios Chondrogiannis ◽

Maria Cristina Marzola ◽

Anna Margherita Maffione ◽

...

Keyword(s):

Head And Neck Cancer ◽

Head And Neck ◽

Fdg Pet ◽

Cross Sectional ◽

Pet Ct ◽

Cross Sectional Imaging ◽

18F Fdg ◽

Sectional Imaging ◽

Fdg Pet Ct

Download Full-text

Preliminary experience with 18f-fluoro-deoxy-glucose positron emission tomography/computed tomography in pediatric oncology patients

Acta chirurgica iugoslavica ◽

10.2298/aci1104067o ◽

2011 ◽

Vol 58 (4) ◽

pp. 67-73

Author(s):

Strahinja Odalovic ◽

Dragana Sobic-Saranovic ◽

Smiljana Pavlovic ◽

Isidora Grozdic ◽

Djordjije Saranovic ◽

...

Keyword(s):

Pediatric Oncology ◽

Fdg Pet ◽

Pediatric Patients ◽

Distant Metastases ◽

Oncology Patients ◽

Positron Emission ◽

Clinical Center ◽

Pet Ct ◽

Residual Masses ◽

Fdg Pet Ct

The aim of this study was to present preliminary experience with FDG PET/CT in pediatric oncology patients in National PET Center, Clinical Center of Serbia and to asses its impact on management of malignancies in children. 33 FDG PET /CT scans were performed on 30 pediatric patients. PET/CT imaging was performed for staging the disease, assessing therapy efficacy and diagnosing recurrent or metastatic disease. FDG PET/CT changed the stage of the disease in 60.6 % (20/33) of the cases. 14 patients were down-staged after PET/CT, mostly patients with Hodgkin?s disease, were in 7/10 cases PET/CT showed no activity in residual masses. Six scans led to upstage of the disease. In three cases PET/CT did not change the stage of disease, but has showed new distant metastases. In conclusion, FDG PET/CT showed important role in managing pediatric patients with different malignancies and was useful complementary diagnostic tool to conventional imaging methods.

Download Full-text

Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up18F-FDG PET/CT Scans in Oncology Patients

Journal of Nuclear Medicine ◽

10.2967/jnumed.116.183111 ◽

2016 ◽

Vol 58 (5) ◽

pp. 737-743 ◽

Cited By ~ 6

Author(s):

Mehdi Taghipour ◽

Charles Marcus ◽

Sara Sheikhbahaei ◽

Esther Mena ◽

Shwetha Prasad ◽

...

Keyword(s):

Fdg Pet ◽

Ct Scans ◽

Oncology Patients ◽

Clinical Indications ◽

Pet Ct ◽

Fdg Pet Ct

Download Full-text

Skeletal Muscle Metrics on Clinical 18F- FDG PET/CT Predict Health Outcomes in Patients with Sarcoma

10.1101/304279 ◽

2018 ◽

Cited By ~ 1

Author(s):

Brent Foster ◽

Robert D. Boutin ◽

Leon Lenchik ◽

David Gedeon ◽

Yu Liu ◽

...

Keyword(s):

Skeletal Muscle ◽

Health Outcomes ◽

Fdg Pet ◽

Cancer Recurrence ◽

Standardized Uptake Value ◽

Muscle Area ◽

Cross Sectional ◽

Reactive Protein ◽

Pet Ct ◽

Fdg Pet Ct

ABSTRACTThe aim of this study was to determine the association of measures of skeletal muscle determined from 18F-FDG PET/CT with health outcomes in patients with soft-tissue sarcoma. 14 patients (8 women and 6 men; mean age 66.5 years) with sarcoma had PET/CT examinations. On CTs of the abdomen and pelvis, skeletal muscle was segmented, and cross-sectional muscle area, muscle volume, and muscle attenuation were determined. Within the segmented muscle, intramuscular fat area, volume, and density were derived. On PET images the standardized uptake value (SUV) of muscle was determined. Regression analyses were conducted to determine the association between the imaging measures and health outcomes including overall survival (OS), local recurrence-free survival (LRFS), distant cancer recurrence (DCR), and major surgical complications (MSC). The association between imaging metrics and pre-therapy levels of serum C-reactive protein (CRP), creatinine, hemoglobin, and albumin was determined. Decreased volumetric muscle CT attenuation was associated with increased DCR. Increased PET SUV of muscle was associated with decreased OS and LRFS. Lower muscle SUV was associated with lower serum hemoglobin and albumin. Muscle measurements obtained on routine 18F-FDG PET/CT is associated with outcomes and serum hemoglobin and albumin in patients with sarcoma.

Download Full-text

Comparison of SUVmax Values Obtained from F-18 FDG PET/CT and Cell-free DNA Levels Measured from Plasma in Oncology Patients

Molecular Imaging and Radionuclide Therapy ◽

10.4274/mirt.galenos.2019.60352 ◽

2019 ◽

Vol 28 (2) ◽

pp. 46-52

Author(s):

Fatmanur Çelik ◽

Yusuf Ziya Tan ◽

Semra Özdemir ◽

Fatma Sılan

Keyword(s):

Fdg Pet ◽

Oncology Patients ◽

Cell Free Dna ◽

Free Dna ◽

Pet Ct ◽

Fdg Pet Ct

Download Full-text

Brain metastases assessment by FDG-PET/CT: can it eliminate the necessity for dedicated brain imaging?

Egyptian Journal of Radiology and Nuclear Medicine ◽

10.1186/s43055-020-00342-8 ◽

2020 ◽

Vol 51 (1) ◽

Author(s):

Mamdouh A. Zidan ◽

Radwa S. Hassan ◽

Khaled I. El-Noueam ◽

Yasser M. Zakaria

Keyword(s):

Brain Metastases ◽

Fdg Pet ◽

Diagnostic Performance ◽

Imaging Modality ◽

False Negative ◽

Whole Body ◽

Cross Sectional ◽

Primary Tumors ◽

Pet Ct ◽

Fdg Pet Ct

Abstract Background Brain metastases (BM) are the most common intracranial tumors in adults outnumbering all other intracranial neoplasms. Positron emission tomography combined with computed tomography (PET/CT) is a widely used imaging modality in oncology with a unique combination of cross-sectional anatomic information provided by CT and the metabolic information provided by PET using the [18F]-2-fluoro-2-deoxy-d-glucose (FDG) as a tracer. The aim of the study is to assess the role and diagnostic performance of brain-included whole-body PET/CT in detection and evaluation of BM and when further imaging is considered necessary. The study was conducted over a period of 12 months on 420 patients suffering from extra-cranial malignancies utilizing brain-included whole-body PET/CT. Results Thirty patients with 71 brain lesions were detected, 18 patients (60%) had BM of unknown origin while 12 patients (40%) presented with known primary tumors. After brain-included whole-body FDG-PET/CT examination, the unknown primaries turned out to be bronchogenic carcinoma in 10 patients (33.3%), renal cell carcinoma in 2 patients (6.7%), and lymphoma in 2 patients (6.7%), yet the primary tumors remained unknown in 4 patients (13.3%). In 61 lesions (85.9%), the max SUV ranged from 0.2- < 10, while in 10 lesions (14.1%) the max SUV ranged from 10 to 20. Hypometabolic lesions were reported in 41 (57.7%) lesions, hypermetabolic in 3 lesions (4.2%), whereas 27 lesions (38.0%) showed similar FDG uptake to the corresponding contralateral brain matter. PET/CT overall sensitivity, specificity, positive and negative predictive, and accuracy values were 78.1, 92.6, 83.3, 90, and 88% respectively. Conclusion Brain-included whole-body FDG-PET/CT provides valuable complementary information in the evaluation of patients with suspected BM. However, the diagnostic performance of brain PET-CT carries the possibility of false-negative results with consequent false sense of security. The clinicians should learn about the possible pitfalls of PET/CT interpretation to direct patients with persistent neurological symptoms or high suspicion for BM for further dedicated CNS imaging.

Download Full-text